Bachem Holding (BANB) Hisse Özeti
Bachem Holding AG, iştirakleriyle birlikte, dünya çapındaki ilaç ve biyoteknoloji şirketlerine araştırma, klinik geliştirme ve ticari uygulama için ürünler sağlamaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 3/6 |
| Gelecekteki Büyüme | 3/6 |
| Geçmiş Performans | 5/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 3/6 |
BANB Community Fair Values
Create NarrativeSee what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
CHF 249.99
FV
69.0% değerinin altında içsel indirim62.01%
Revenue growth p.a.
159
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Bachem Holding AG Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | CHF 77.55 |
| 52 Haftanın En Yüksek Seviyesi | CHF 83.25 |
| 52 Haftanın En Düşük Seviyesi | CHF 48.52 |
| Beta | 0.81 |
| 1 Aylık Değişim | 14.21% |
| 3 Aylık Değişim | 16.09% |
| 1 Yıllık Değişim | 33.59% |
| 3 Yıllık Değişim | 4.59% |
| 5 Yıllık Değişim | -31.61% |
| Halka arzdan bu yana değişim | 453.93% |
Son Haberler & Güncellemeler
Analiz Makalesi • 31m
Does Bachem Holding (VTX:BANB) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Anlatı Güncellemesi • Jun 22
BANB: Capacity Expansion Commitments Will Heighten Execution Risk And Restrain Upside
Analysts have raised their price target on Bachem Holding by CHF 5 to reflect updated assumptions for discount rates, growth and profitability. This move is supported by recent Street research that cites a higher target from CHF 5 at Barclays as a reference point for the new CHF level.
Anlatı Güncellemesi • Jun 05
BANB: Future Upside Will Rely On Executing Margin Assumptions And Higher P E Framework
Analysts have raised their CHF price targets on Bachem Holding, including recent CHF 5 and CHF 5 increases from two major banks, reflecting updated views on growth, margins, and future P/E assumptions. Analyst Commentary Bullish analysts are signaling a constructive view on Bachem Holding, pointing to updated price targets that reflect their latest assumptions on growth, margins, and valuation.Anlatı Güncellemesi • May 22
BANB: Higher Assumed Growth Will Exacerbate Execution Risk And Limit Upside
Analysts have nudged their price targets for Bachem Holding higher, with recent Street research citing revised assumptions for growth, margins and P/E that collectively support a modestly higher fair value approach in CHF terms. Analyst Commentary Recent price target revisions for Bachem Holding sit in a fairly tight range, with updates clustered around the CHF 80 level.Recent updates
Analiz Makalesi • 31m
Does Bachem Holding (VTX:BANB) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Anlatı Güncellemesi • Jun 22
BANB: Capacity Expansion Commitments Will Heighten Execution Risk And Restrain Upside
Analysts have raised their price target on Bachem Holding by CHF 5 to reflect updated assumptions for discount rates, growth and profitability. This move is supported by recent Street research that cites a higher target from CHF 5 at Barclays as a reference point for the new CHF level.Anlatı Güncellemesi • Jun 05
BANB: Future Upside Will Rely On Executing Margin Assumptions And Higher P E Framework
Analysts have raised their CHF price targets on Bachem Holding, including recent CHF 5 and CHF 5 increases from two major banks, reflecting updated views on growth, margins, and future P/E assumptions. Analyst Commentary Bullish analysts are signaling a constructive view on Bachem Holding, pointing to updated price targets that reflect their latest assumptions on growth, margins, and valuation.Anlatı Güncellemesi • May 22
BANB: Higher Assumed Growth Will Exacerbate Execution Risk And Limit Upside
Analysts have nudged their price targets for Bachem Holding higher, with recent Street research citing revised assumptions for growth, margins and P/E that collectively support a modestly higher fair value approach in CHF terms. Analyst Commentary Recent price target revisions for Bachem Holding sit in a fairly tight range, with updates clustered around the CHF 80 level.
Anlatı Güncellemesi • May 01
BANB: Future Earnings Execution Is Expected To Support CHF 80 Upside Potential
Analysts have nudged their price target on Bachem Holding slightly higher, with recent Street research indicating a CHF 5 increase from both Barclays and Deutsche Bank to CHF 80, supported by updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a CHF 80 target as aligned with their updated view on fair value, suggesting that current assumptions on growth and margins justify a higher valuation anchor.
Yeni Anlatı • Apr 26
Bachem Holding - The Purest Public Peptide Play?
We are living through a biological revolution. You see it on the balance sheets of the world’s largest pharmaceutical companies and you see it in the cultural zeitgeist.Anlatı Güncellemesi • Apr 16
BANB: Future Upside Will Depend On Executing Profit Margin Assumptions
Narrative Update Bachem Holding's updated analyst price target now reflects a modest recalibration in assumptions, with recent CHF 5, CHF 80, and CHF 32 target increases cited by analysts who point to slightly higher profit margin expectations and a small adjustment to the assumed P/E multiple as key drivers. Analyst Commentary Recent research updates on Bachem Holding have leaned constructive, with bullish analysts adjusting their price targets upward and citing a mix of valuation and execution factors.Anlatı Güncellemesi • Apr 02
BANB: Future Execution On Project Pipeline Will Support CHF 80 Upside Potential
Narrative Update Analyst price targets for Bachem Holding have shifted to a range of CHF 60 to CHF 80, with the upper end raised from CHF 75, as analysts reflect updated views on the company in their valuation work. Analyst Commentary Recent research updates on Bachem Holding point to a split in how analysts see the risk and reward around the stock, which feeds directly into the current CHF 60 to CHF 80 price target range.Anlatı Güncellemesi • Mar 19
BANB: Future Execution On Growth Plans Will Support Higher CHF 80 Upside Potential
Analysts have nudged the consolidated price target for Bachem Holding to CHF 80, up CHF 5 from prior levels, citing updated assumptions for growth, profitability and a slightly lower P/E outlook that align with recent Street research moves. Analyst Commentary Street research on Bachem Holding has been mixed, with some analysts lifting price targets toward CHF 80 while others are more hesitant and keep targets closer to CHF 60.Anlatı Güncellemesi • Mar 05
BANB: Future Execution On Pipeline Plans Will Support Higher Market Confidence
The updated analyst price target for Bachem Holding suggests a modest upward revision to fair value to CHF 78.66, with analysts citing slightly adjusted assumptions for the discount rate, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher price target as a signal that their assumptions for Bachem Holding’s future earnings and cash flows now support a fair value above the prior level, even after revisiting discount rate and P/E inputs.Anlatı Güncellemesi • Feb 18
BANB: Future Pipeline Execution Will Drive Upside Versus Recent Cautious Views
Analysts have adjusted their fair value estimate for Bachem Holding to CHF 76.59, reflecting updated views on growth, profitability and valuation following recent price target revisions that include a CHF 32 increase from RBC Capital and a reduction to CHF 60 from Barclays. Analyst Commentary Recent research shows a split view on Bachem Holding, with some bullish analysts lifting targets and more cautious voices trimming expectations.Anlatı Güncellemesi • Feb 04
BANB: Higher Fair Value Will Rely On Execution Of Existing Order Book
Analysts have raised their fair value estimate for Bachem Holding from CHF 100.00 to CHF 110.00, citing updated assumptions around revenue growth, profit margins and future P/E multiples that are in line with recent Street target changes, including the higher price target from RBC and the revised level from Barclays. Analyst Commentary Recent research updates around Bachem Holding give you a mixed but useful read on how the Street is thinking about valuation and execution.Anlatı Güncellemesi • Jan 21
BANB: Building K Execution Risks Will Limit Future Share Upside
Analysts have nudged their price target on Bachem Holding slightly lower to about CHF 60 to CHF 75, reflecting updated assumptions around discount rates, revenue growth near 21.5% and an expected future P/E close to 18.9%. They are also weighing recent research that includes a reduced CHF 60 target alongside a CHF 75 target tied to the company’s Building K expansion plans.Anlatı Güncellemesi • Jan 07
BANB: Building K Execution Risk Will Constrain Future Upside Potential
Analysts have trimmed their average price target on Bachem Holding to CHF 60 from CHF 75, citing updated assumptions for revenue growth, profit margins and future P/E multiples that reflect a more measured outlook, even as expansion projects remain in focus. Analyst Commentary Recent street research on Bachem highlights a mix of views, with some analysts seeing potential tied to expansion projects such as Building K, while others are recalibrating expectations and price targets to reflect what they view as a more balanced risk and reward profile.Anlatı Güncellemesi • Dec 14
BANB Building K Expansion Will Define Future Upside And Execution Risk
Analysts have raised their price target for Bachem Holding from approximately CHF 58 to about CHF 75, citing increased confidence in revenue growth driven by the company's Building K expansion project, despite a slightly higher discount rate and modestly lower profit margin and valuation multiples. Analyst Commentary Recent research commentary highlights a more constructive stance on Bachem Holding, with the upgraded price target to CHF 75 framed around the growth potential from the Building K expansion project.Analiz Makalesi • Dec 01
At CHF51.85, Is Bachem Holding AG (VTX:BANB) Worth Looking At Closely?
While Bachem Holding AG ( VTX:BANB ) might not have the largest market cap around , it received a lot of attention from...Analiz Makalesi • Oct 25
Bachem Holding AG's (VTX:BANB) Price In Tune With Earnings
Bachem Holding AG's ( VTX:BANB ) price-to-earnings (or "P/E") ratio of 32x might make it look like a strong sell right...Anlatı Güncellemesi • Sep 26
Building K Production Will Serve Peptide And Oligonucleotide Therapies
Bachem Holding's fair value has been revised downward, primarily reflecting slight declines in both its discount rate and future P/E ratio, with the consensus analyst price target decreasing from CHF77.88 to CHF74.70. What's in the News Maintained 2026 sales guidance of over CHF 1 billion and profitability above 30%.Analiz Makalesi • Sep 18
Bachem Holding (VTX:BANB) Ticks All The Boxes When It Comes To Earnings Growth
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analiz Makalesi • Aug 16
Bachem Holding (VTX:BANB) Seems To Use Debt Quite Sensibly
SWX:BANB 1 Year Share Price vs Fair Value Explore Bachem Holding's Fair Values from the Community and select yours Some...Analiz Makalesi • Jul 30
Bachem Holding's (VTX:BANB) Profits May Not Reveal Underlying Issues
The market for Bachem Holding AG's ( VTX:BANB ) stock was strong after it released a healthy earnings report last week...Analiz Makalesi • Jul 25
Bachem Holding AG's (VTX:BANB) P/E Is Still On The Mark Following 28% Share Price Bounce
Bachem Holding AG ( VTX:BANB ) shares have continued their recent momentum with a 28% gain in the last month alone. But...
Yeni Anlatı • Mar 02
Building K And 24-Hour Operations Will Improve Efficiency
Capacity expansion and 24/7 operations enhance production, reduce costs, and bolster revenue growth in response to rising demand for peptides and oligonucleotides.Hissedar Getirileri
| BANB | CH Life Sciences | CH Pazar | |
|---|---|---|---|
| 7D | 7.9% | 7.1% | 1.8% |
| 1Y | 33.6% | 4.6% | 18.1% |
Getiri vs. Endüstri: BANB geçen yıl % 4.6 oranında getiri sağlayan Swiss Life Sciences sektörünü aştı.
Getiri vs Piyasa: BANB geçen yıl % 18.1 oranında getiri sağlayan Swiss Piyasasını aştı.
Fiyat Oynaklığı
| BANB volatility | |
|---|---|
| BANB Average Weekly Movement | 5.9% |
| Life Sciences Industry Average Movement | 6.0% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in CH Market | 7.4% |
| 10% least volatile stocks in CH Market | 2.1% |
İstikrarlı Hisse Senedi Fiyatı: BANB hisse senedi fiyatı, son 3 ayda Swiss piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: BANB 'nin haftalık oynaklığı ( 6% ) geçen yıl boyunca sabit kaldı, ancak hala Swiss hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1971 | 2,363 | Anne-Kathrin Stoller | www.bachem.com |
Bachem Holding AG, iştirakleri ile birlikte, dünya çapında ilaç ve biyoteknoloji şirketlerine araştırma, klinik geliştirme ve ticari uygulama için ürünler sağlamaktadır. Peptit ve oligonükleotit yeni kimyasal varlıklar (NCE'ler) gibi peptit aktif farmasötik bileşenlerin geliştirilmesi, üretimi ve düzenleyici desteği ile ilgilenmektedir. Şirket ayrıca ticari NCE'ler ve jenerikler; ve proje yönetimi, kalite ve düzenleyici, analitik, iyi üretim uygulamaları üretimi, araştırma sınıfı üretim ve tedarik ve dikey entegrasyon hizmetleri sunmaktadır.
Bachem Holding AG Temel Bilgiler Özeti
| BANB temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | CHF 5.81b |
| Kazançlar(TTM) | CHF 148.79m |
| Gelir(TTM) | CHF 695.07m |
39.1x
F/K Oranı8.4x
P/S OranıBANB aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| BANB gelir tablosu (TTM) | |
|---|---|
| Gelir | CHF 695.07m |
| Gelir Maliyeti | CHF 495.34m |
| Brüt Kâr | CHF 199.73m |
| Diğer Giderler | CHF 50.94m |
| Kazançlar | CHF 148.79m |
Son Raporlanan Kazançlar
Dec 31, 2025
Sonraki Kazanç Tarihi
Jul 30, 2026
| Hisse başına kazanç (EPS) | 1.99 |
| Brüt Marj | 28.74% |
| Net Kâr Marjı | 21.41% |
| Borç/Özkaynak Oranı | 3.9% |
BANB uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
1.2%
Mevcut Temettü Verimi45%
Ödeme OranıŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/03 06:41 |
| Gün Sonu Hisse Fiyatı | 2026/07/03 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Bachem Holding AG 17 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Charles Pitman | Barclays |
| Estelle Bétrisey | Berenberg |
| Patrick Laager | Berenberg |